1
|
Tong X, Zhan T, Dong X, Xu D. Fever of unknown origin associated with immune checkpoint inhibitors. Front Immunol 2024; 15:1364128. [PMID: 38533499 PMCID: PMC10963505 DOI: 10.3389/fimmu.2024.1364128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Accepted: 02/29/2024] [Indexed: 03/28/2024] Open
Abstract
Since the approval for the treatment of melanoma in 2014, immune checkpoint inhibitors (ICIs) have revolutionized the therapy pattern across various malignancies. Coinciding with their frequent usage, their adverse effects, including fever, cannot be neglected. In the context of cancer diseases and cancer treatments, fever of unknown origin (FUO), which has long posed a challenge for clinicians in terms of diagnosis and management, brings forth new connotation and significance. In this paper review, we present the concept of ICIs-associated FUO, consider activated immune system and elevated cytokines as common mechanisms by which ICIs induce fever and various immune-related adverse events (irAEs), summarize and compare the primary etiologies of ICI-associated FUO, and compare it with conventional types of FUO.
Collapse
Affiliation(s)
- Xu Tong
- The Second Clinical Medical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Tao Zhan
- The Second Clinical Medical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Xiaoqin Dong
- Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Dong Xu
- Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan, Hubei, China
| |
Collapse
|
2
|
Sakuranaka H, Nakagawa T, Yokota S, Takahashi E, Yamakawa Y, Hirata A, Igei K, Okamoto N, Ichioka M. Unilateral methotrexate-induced lung injury with foreign bodies in the airway: A case report. Respir Med Case Rep 2022; 36:101573. [PMID: 35036304 PMCID: PMC8749056 DOI: 10.1016/j.rmcr.2021.101573] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 12/30/2021] [Indexed: 11/18/2022] Open
Abstract
A 75-year-old woman who had been taking methotrexate presented to our hospital for fever and dry cough. Chest computed tomography showed ground-glass opacity in the upper lobe of the right lung and foreign bodies in the lower lobe of the right bronchus. During bronchoscopy, foreign bodies were removed from the airway. We found increased levels of lymphocytes and a high CD4/CD8 ratio in the bronchoalveolar lavage fluid. Transbronchial lung biopsy revealed lymphocytic infiltration. Methotrexate was discontinued, and the imaging findings improved. Methotrexate-induced lung injury does occur unilaterally. Foreign bodies in the airway might also trigger unilateral methotrexate-induced lung injury.
Collapse
Affiliation(s)
- Haruyasu Sakuranaka
- Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
- Corresponding author.
| | - Takashi Nakagawa
- Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
- Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-Ku, Tokyo, 173-8601, Japan
| | - Shun Yokota
- Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-Ku, Tokyo, 173-8601, Japan
| | - Eichi Takahashi
- Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
- Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-Ku, Tokyo, 173-8601, Japan
| | - Yuji Yamakawa
- Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
| | - Akifumi Hirata
- Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-Ku, Tokyo, 173-8601, Japan
| | - Koumei Igei
- Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
- Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-Ku, Tokyo, 173-8601, Japan
| | - Naoki Okamoto
- Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
| | - Masahiko Ichioka
- Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
| |
Collapse
|
3
|
Abstract
Glioblastoma has emerged as an immunotherapy-refractory tumor based on negative phase III studies of anti-programmed cell death-1 therapy among newly diagnosed as well as recurrent patients. In addition, although much work on vaccine and cellular approaches is ongoing, therapeutic benefit with these approaches has been underwhelming. Much scientific insight into the multitiered layers of immunosuppression exploited by glioblastoma tumors is emerging that sheds light on the explanation for the disappointing results to date and highlights possible therapeutic avenues that may offer a better likelihood of therapeutic benefit for immune-based therapies.
Collapse
|
4
|
Villa-Ruano N, Guerrero-González T, Gómez-Conde E, Perez-Santos M. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232. Expert Opin Ther Pat 2020; 30:723-727. [PMID: 32787475 DOI: 10.1080/13543776.2020.1810238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION PD-L1 and PD-1 are two immune checkpoints and their presence in various types of tumors is related to a poor prognosis; this makes them highly relevant targets in the development of new therapies. Patent US2019010232 describes bispecific anti-PD-L1/PD-1 antibodies made with Azymetric technology. AREAS COVERED Three bispecific antibodies that target PD-L1/PD-1 are described in US2019010232 patent and are proposed to play a relevant role in the treatment of cancer. EXPERT OPINION Three bispecific antibodies that target PD-L1/PD-1 in US2019010232 demonstrated anti-tumor activity in lung cancer. However, no evidence is shown of the action of the antibodies against other cancers. An advantage of the bispecific antibodies of US2019010232 over combinatorial therapy is a greater decrease in tumor volume.
Collapse
Affiliation(s)
- Nemesio Villa-Ruano
- Innovation and Knowledge Transfer Department, Benemerita Autonomous University of Puebla , Puebla, Mexico.,Consejo Nacional de Ciencia y Tecnología, Ciudad de México, Cátedras CONACYT , México
| | - Tayde Guerrero-González
- Traumatology and Orthopedics Service, Regional Hospital 1o. De Octubre, Institute of Security and Social Services for State Workers , Madero, México
| | - Eduardo Gómez-Conde
- Research Laboratory in Immunobiology, Faculty of Medicine, Benemerita Autonomous University of Puebla , Puebla, Mexico
| | - Martin Perez-Santos
- Innovation and Knowledge Transfer Department, Benemerita Autonomous University of Puebla , Puebla, Mexico
| |
Collapse
|
5
|
Kim EY, Kim YS, Park I, Ahn HK, Lee HY, Kim JH. Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy. J Thorac Dis 2018; 10:S3930-S3932. [PMID: 30631519 DOI: 10.21037/jtd.2018.09.129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Eun Young Kim
- Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
| | - Young Saing Kim
- Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
| | - Inkeun Park
- Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
| | - Hee Kyung Ahn
- Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
| | - Hee Young Lee
- Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
| | - Jeong Ho Kim
- Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
| |
Collapse
|
6
|
Hammer M, Bagley S, Aggarwal C, Bauml J, Nachiappan AC, Simone CB, Langer C, Katz SI. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy. Curr Probl Diagn Radiol 2018; 48:142-147. [PMID: 29573843 DOI: 10.1067/j.cpradiol.2018.01.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2017] [Accepted: 01/08/2018] [Indexed: 01/09/2023]
Abstract
PURPOSE Treatment with anti-programmed death receptor-1 (PD-1) therapeutics can lead to unconventional responses and side effect profiles due to their potentiating effects on the immune system. Here we evaluate the radiologic manifestations of anti-PD-1 therapy in the chest in patients with non-small cell lung cancer (NSCLC) receiving anti-PD-1 therapy. MATERIALS AND METHODS A retrospective review of real-world clinical practice was conducted of all the patients with NSCLC receiving anti-PD-1 therapy at our institution between 2013 and 2016. All patients without adequate clinical or radiologic follow-up data in the electronic medical records were excluded. Imaging examinations for all patients deemed by their thoracic oncologists to have radiologic pseudoprogression or therapy-associated pneumonitis were reviewed by experienced thoracic radiologists. RESULTS A total of 166 patients with NSCLC had available clinical and imaging data for retrospective review. Of these patients, 4 (2%) were considered to have radiologic pseudoprogression, 3 of which manifested as increased tumor size and 1 of which manifested with new lesions. A total of 5 patients (3%) were clinically deemed to have pneumonitis attributable to anti-PD-1 therapy, 4 of which had radiologic manifestations on computed tomography. CONCLUSION Radiologic pseudoprogression and drug-induced pneumonitis are uncommon but important manifestations of anti-PD-1 therapy on thoracic imaging.
Collapse
Affiliation(s)
- Mark Hammer
- Department of Radiology, Brigham and Women's Hospital, Boston, MA; Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Stephen Bagley
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Charu Aggarwal
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Joshua Bauml
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Arun C Nachiappan
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Charles B Simone
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - Corey Langer
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Sharyn I Katz
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
| |
Collapse
|